United States Patent 11,045,474 Scope, Claims, and Patent Landscape (Jakafi and LY3009104/INCB28050 for Coronaviridae Infection)
Executive summary: U.S. Patent 11,045,474 claims treatment methods for Coronaviridae infections using (i) Jakafi (ruxolitinib) and (ii) LY3009104/INCB28050, plus a dependent claim to LY3009104/INCB28050 and a separate independent method claim to tofacitinib. The claim set is limited to method-of-treatment with specific named kinase inhibitors. Enforceability and freedom-to-operate in the U.S. will turn on (a) how broadly “Coronaviridae infection” is construed across coronavirus species, (b) whether existing ruxolitinib/tofacitinib method claims in other patents already cover the same clinical use, (c) the status of any COVID-era coronavirus method patents with overlapping subject matter, and (d) how Orange Book listing and any related method-of-use drug patents map to the same labels or off-label uses.
What does US Patent 11,045,474 claim for Coronaviridae infection treatment methods?
Short answer: It claims methods of treating Coronaviridae infections by administering an “effective antiviral amount” of one of the following:
- Jakafi (ruxolitinib)
- LY3009104 / INCB28050
- Tofacitinib (as a separate method claim)
Independent claim 1 scope
Claim 1 is a species-by-name treatment method that uses:
- Therapeutic target: “Coronaviridae infection”
- Therapeutic action: “treating”
- Drug class selection: “a compound selected from the group consisting of Jakafi, and LY3009104/INCB28050”
- Exposure term: “administering an effective, antiviral amount”
- Patient: “a patient in need of treatment”
Key scope characteristics
- The drug universe is closed (“group consisting of”), limited to Jakafi and LY3009104/INCB28050.
- The clinical/virology endpoint is framed generically as “Coronaviridae infection,” not restricted to one virus (e.g., SARS-CoV-2 only).
- The exerted effect is “antiviral amount,” not an immunomodulatory dose metric.
Dependent claim 2
Claim 2 narrows claim 1 by specifying:
- The compound is LY3009104/INCB28050.
Independent claim 3 scope (tofacitinib)
Claim 3 claims the same “method of treating Coronaviridae infection” but with:
- “administering an effective, antiviral amount of Tofacitinib.”
Claim architecture implication: claim 3 is drafted as a separate independent claim rather than a member of the “group consisting of” in claim 1.
How broad is “Coronaviridae infection” in US 11,045,474, and how does that affect enforceability?
Short answer: “Coronaviridae infection” is broad at the taxonomic family level; infringement arguments typically hinge on whether the asserted use covers the specific coronavirus family member being treated and whether the accused product was administered in an “antiviral” effective amount for treating that infection.
Virus coverage across the Coronaviridae family
“Coronaviridae” includes multiple subfamilies and genera associated with human infection, commonly including:
- Alpha- coronaviruses (e.g., transmissible across species)
- Beta- coronaviruses, including the major human pathogens
Because the claim does not restrict to a particular coronavirus species, the literal scope can extend across coronaviridae infections, including but not limited to SARS-CoV-2, depending on claim construction and evidentiary record.
“Antiviral amount” is a claim-interpretation flashpoint
The claims require “effective, antiviral amount,” which is likely to be interpreted as an amount that provides antiviral therapeutic effect for the claimed infection. For enforcement, this usually means:
- accused dosing regimens show antiviral effect or are clinically framed as antiviral treatment for coronaviridae infection, or
- the specification supports “antiviral” meaning for the claimed compounds.
Method claims hinge on acts of administration
Unlike compound patents, these claims focus on:
- dosing
- patient selection
- treatment purpose
- clinical practice context
That makes infringement less about chemical composition and more about how the drug was used.
What patents protect using ruxolitinib (Jakafi) for Coronaviridae infection in the United States?
Short answer: U.S. Patent 11,045,474 covers a method-of-use using Jakafi (ruxolitinib) as an “effective, antiviral amount” to treat Coronaviridae infection. The broader ruxolitinib landscape typically includes (i) composition and formulation patents for the branded drug, and (ii) method-of-use patents in inflammatory/immune indications that can overlap conceptually with antiviral or infection uses. The decisive issue is whether those other patents cover the same infection-treatment claims or instead cover different endpoints.
How to map 11,045,474 into a broader ruxolitinib estate
A practical patent estate mapping for ruxolitinib for coronaviridae uses generally looks for:
- method-of-treatment coronavirus claims (often COVID-era filings)
- method-of-use immunomodulation claims that may be argued to read on antiviral dosing protocols
- combination regimens (if any exist in the same prosecution history/specification)
- formulation patents that could affect design-around but not necessarily method infringement
What patents protect LY3009104 / INCB28050 for Coronaviridae infection?
Short answer: Claim 1 and claim 2 of U.S. Patent 11,045,474 specifically cover LY3009104 / INCB28050 as a named compound for the “method of treating a Coronaviridae infection” with an “effective, antiviral amount.”
What that means for licensing and design-around
Because the claim names the compound(s), circumvention by using:
- a different JAK inhibitor,
- a different dosage form without changing the active,
- or an alternate dosing regimen
may reduce risk only if it avoids the “effective antiviral amount” elements as construed, not merely by changing excipients.
What patents protect tofacitinib for Coronaviridae infection?
Short answer: Claim 3 is an independent method claim for treating Coronaviridae infection with tofacitinib at an “effective, antiviral amount.”
Design-around pressure
A competitor seeking to use tofacitinib to treat coronaviridae infection in the U.S. faces a direct method claim. Practical risk mitigation typically involves:
- avoiding the claimed treatment purpose and/or dosing context, or
- selecting different active ingredients not covered by the specific claim language.
Because claim 3 is not part of a “group consisting of” closure tied to claim 1, designing around may require avoiding tofacitinib entirely for the same claimed use.
How many claims are in US 11,045,474 and what is the effective coverage unit?
Short answer: Based on the claim set provided, there are three claims relevant to the described scope:
- method using Jakafi or LY3009104/INCB28050
- dependent narrowing to LY3009104/INCB28050
- method using tofacitinib
Coverage unit: each claim is a method of treatment claim; the enforceable “thing” is not the molecule but the clinical act of administering it to treat a coronaviridae infection at an effective antiviral amount.
When does U.S. Patent 11,045,474 lose exclusivity: expiration versus regulatory exclusivity?
Short answer: Loss of exclusivity is governed by patent expiration (and any applicable patent term adjustments) and any separate regulatory exclusivity (e.g., exclusivity tied to an FDA approval). A method-of-use patent can still be enforceable even when compound exclusivity ends, because it can block labeling or marketing efforts that induce the claimed method.
Critical practical point for business decisions: For U.S. entry risk, the relevant date is the earliest date on which the asserted method claims can be practiced without infringement exposure, factoring:
- expiration of the patent,
- any terminal disclaimers,
- any injunctions or stays,
- and validity outcomes if there is litigation (not provided here).
What is the Orange Book status of US 11,045,474?
Short answer: An Orange Book listing depends on whether this patent is listed as an approved drug product patent and, if so, whether it is listed under:
- Drug Substance,
- Drug Product,
- or Method of Use.
However: the required metadata (NDC listings, Orange Book patent numbers tied to the specific NDA/BLA, and listing codes) is not provided here, so the Orange Book status cannot be deterministically mapped from the claim text alone.
What generic entry risks exist for Jakafi, LY3009104/INCB28050, and tofacitinib if 11,045,474 is enforced?
Short answer: Even if generic ruxolitinib or generic tofacitinib are approved, the method claims can create use-based infringement risk when generics are marketed, promoted, or used in a manner that practices the claimed “Coronaviridae infection” antiviral treatment method.
Key infringement pathways for generics
- Direct infringement: patient treatment with the claimed dosing regimen
- Induced infringement: marketing materials, labeling, or physician instructions that encourage practice of the claimed method
- Contributory infringement: providing a component or drug with knowledge of the method and intent that it be used in the claimed manner
Why approval alone is not the end-state
Because these are method-of-use claims, even fully genericized chemistry can still face litigation risk if the clinical use is covered and inducement theories are supported.
What formulation patents could interact with this method-of-use estate?
Short answer: U.S. Patent 11,045,474 is a method claim, so formulation patents usually do not determine infringement by themselves. Still, formulation patents can raise operational barriers by controlling:
- dosage form design,
- stability and release characteristics,
- bioequivalence-linked development,
- and labeling strategies.
In practice, if a generic or biosimilar maker wants to change dosage form or drug product while still using the active ingredient, it can create freedom-to-operate constraints under other patents, even if method infringement is avoided.
How does 11,045,474 compare with other COVID-era coronavirus treatment method patents for JAK inhibitors?
Short answer: The differentiator in 11,045,474 is its claim language that names specific JAK inhibitors:
- ruxolitinib (Jakafi)
- LY3009104/INCB28050
- tofacitinib
Many other coronavirus method patents either:
- cover broader classes without naming specific drugs, or
- cover specific combinations, or
- focus on specific viral mechanisms and biomarkers.
Business implication: named-compound claims are harder to design around because switching to a different drug is a straightforward way to avoid literal coverage, but staying on the same drug requires careful use-based assessment.
What patent litigation affects US 11,045,474?
Short answer: No litigation caption, parties, docket numbers, or PTAB history is provided in the prompt, so the litigation effect cannot be determined here.
Key Takeaways
- U.S. Patent 11,045,474 covers method-of-treatment for Coronaviridae infection using Jakafi (ruxolitinib) and LY3009104/INCB28050 (claim 1), with LY3009104/INCB28050 specifically singled out (claim 2).
- It also covers tofacitinib for treating Coronaviridae infection with an “effective, antiviral amount” (claim 3).
- The claim scope is broad on the virus family level (“Coronaviridae”) but narrow on the drug universe (named compounds).
- Practical freedom-to-operate risk is tied to use-based infringement theories, not just whether the active ingredient is generic.
- Orange Book status, expiration dates, and litigation posture are not computable from the claim text alone in the provided input.
FAQs
-
Does U.S. Patent 11,045,474 cover SARS-CoV-2 specifically, or any coronavirus in Coronaviridae?
The claim language is framed at the Coronaviridae family level, not by specific virus name, so coverage depends on claim construction and how “Coronaviridae infection” is treated in the patent record and enforcement theory.
-
If ruxolitinib (Jakafi) becomes fully generic, can generic makers still market for Coronaviridae infection?
Genericization of the drug substance does not eliminate exposure if marketing or promotion induces use that practices the claimed method.
-
Can a provider avoid infringement by changing the dosing schedule while still using ruxolitinib for coronaviridae?
The claims require an “effective, antiviral amount,” so design-around turns on whether the alternative regimen still meets that construed element.
-
Is LY3009104/INCB28050 covered only in claim 1, or also separately in claim 2?
It is covered in claim 1 (as one member of the closed group) and is also explicitly narrowed in claim 2.
-
What is the strongest risk point for an entrant: method infringement or compound/formulation infringement?
For this specific patent, the risk point is method-of-use infringement tied to the claimed “Coronaviridae infection” treatment using the named inhibitors.
References
No source materials were provided beyond the claim text in the prompt, so no external citations can be generated.
